Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

Several other analysts have also issued reports on NBRV. Leerink Swann reiterated an “outperform” rating and issued a $14.00 target price on shares of Nabriva Therapeutics AG in a research report on Thursday, October 27th. HC Wainwright reissued a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday. Finally, Wedbush reissued an “outperform” rating and issued a $17.00 price target on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Nabriva Therapeutics AG presently has a consensus rating of “Buy” and an average target price of $13.15.

Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.09 on Tuesday. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $10.69. The stock’s 50 day moving average is $0.00 and its 200 day moving average is $0.00.

A number of institutional investors have recently modified their holdings of NBRV. Jackson Park Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the second quarter worth approximately $195,000. Opaleye Management Inc. increased its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares during the period. Finally, Baker BROS. Advisors LP purchased a new position in shares of Nabriva Therapeutics AG during the third quarter worth approximately $2,468,000. 63.09% of the stock is currently owned by institutional investors.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

5 Day Chart for NASDAQ:NBRV

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.